Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Market Intelligence Pricing Strategies United Kingdom

UK Aspirin Prices Double In June

Pricewatch UK – June 2020

  • Data

Executive Summary

Aspirin led the generics with the fastest-rising UK prices in June, according to the latest figures from WaveData.

You may also be interested in...



Exemestane Leads May Rises In UK

Exemestane led the steepest price rises for generics seen in the UK in May. However, concession pricing for the breast cancer drug overestimated the actual prices in the market recorded by WaveData.

UK Paracetamol Prices Treble Amid Coronavirus Demand

Average UK trade prices for paracetamol more than trebled in March as the coronavirus outbreak took hold, while the antiviral valaciclovir saw an average increase of over 300%.

UAE’s Bioventure Is Looking For Partners To Expand

Having recently added to its biosimilars alliance with Alvotech, Dubai-based Bioventure says it is looking to expand its international reach through further partnerships.

Table

View full table

Topics

Tags:
Market Intelligence Pricing Strategies United Kingdom
Latest Headlines

Glucagon And Epinephrine Continue To Drive Growth At Amphastar

UAE’s Bioventure Is Looking For Partners To Expand

Is US FDA Preparing to Remove Some Fed Study Requirements For Generic Bioequivalence?

Medicines For Europe Highlights Industry Agenda

See All
UsernamePublicRestriction

Register

GB150076

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By